medigraphic.com

2022, Number 2

<< Back Next >>

Rev Hematol Mex 2022; 23 (2)

Management of Jehovah’s Witnesses with acute lymphoblastic leukemia. Twenty years of experience in a reference hospital in Mexico City

Ramos-Peñafiel C, Martínez-Murillo C, Olarte-Carrillo I, Rozen-Fuller E, Ferrer-Argote V, Pérez-Sámano D, Gallardo-Rodríguez AG, Martínez-Tovar A

Language: English
References: 33
Page: 99-106
PDF size: 297.01 Kb.


ABSTRACT

Objective: To describe the treatments used to extend recommendations for the care of Jehovah’s Witnesses patients.
Materiales and Methods: A retrospective study including patients treated from 1999 to 2019 at the General Hospital of Mexico in Mexico City, Jehovah’s Witnesses who received a treatment scheme for acute lymphoblastic leukemia without transfusion support.
Results: A total of 11 Jehovah’s Witnesses patients, 7 adults (mean age, 41 years) and 4 pediatric patients (mean age, 8 years) were treated. When classifying according to the hemoglobin level, 5/11 patients had hemoglobin levels less than 6 g/dL at diagnosis, 3/11 between 6 to 9 g/L, and 3/11 with levels higher than 10 g/dL. Of the four pediatric patients, all achieved a complete remission; in adults 4/7 achieved a complete remission, and 3/7 had a failure in induction. At the end of the follow up, 6/7 relapsed to bone marrow compared to 2/4 pediatric patients. The different hemoglobin values at diagnosis did not significantly impact survival or the percentage of relapse.
Conclusions: The treatment of Jehovah’s Witnesses patients is possible without transfusion support but with the combination of high doses of sanguineous stimulants to average the prognosis of patients with acute lymphoblastic leukemia.


REFERENCES

  1. Nushantm-Kumari R. Surgical management in treatmentof Jehovah’s witness in trauma surgery in Indian subcontinent.J Emer Trauma Shock 2014; 7 (3): 215- 221. doi:10.4103/0974-2700.136868.

  2. Malkin M, Lenart J, Walsh CA, Woodfin M, Vadi M. Transfusionethics in a pediatric Jehovah’s Witness traumapatient: Simulation case. Mededportal 2016; 12: 10450.doi: 10.15766/mep_2374-8265.10450

  3. Chand NK, Subramanya HB, Rap GV. Management of patientswho refuse blood transfusion. Indian J Anesth 2014;58 (5): 658-664. doi: 10.4103/0019-5049.144680.

  4. Takaschima AK, Sakaee TM, Takaschima AL, Takaschima RD,Lima BJ, Benedetti RH. Ethical and legal duty of anesthesiologistregarding Jehovah’s Witness patient: care protocol.Braz J Anesthesiol 2016; 66 (6): 637-641. doi: 10.1016/j.bjane.2015.03.012.

  5. Poslusny JA Jr, Napolitano LM. How do we treat-life-threateninganemia in a Jehovah’s Witness patient? Transfusion2014; 54 (12): 3026-3034. doi: 10.1111/trf.12888.

  6. Mackenzie CF, Moon-Massat PF, Shander A, JavidrooziM, Greenburg AG. When blood is not an option: factorsaffecting survival after the use of a hemoglobin-basedoxygen Carrier in 54 patients with life-threatening anemia.Anasth Analg 2010; 110 (3): 685-693. doi: 10.1213/ANE.0b013e3181cd473b.

  7. Federeci AB, Vanelli C, Arrigoni L. Transfusion issues incancer patients. Thromb Res 2012; 129 (S1): S60-65. doi:10.1016/S0049-3848(12)70018-X.

  8. Federeci AB, Intini D, Lattuada A, Vanelli C, Arrigoni L,Sacchi E, Russo U. Supportive transfusion therapy incancer patients with acquired defects of hemostasis.Thromb Res 2014; 133 (S2): 56-S62. doi: 10.1016/S0049-3848(14)50010-2.

  9. Tenenbaum T, Hasan C, Kramm CM, Janßen G, et al. Oncologicalmanagement of pediatric cancer patients belongingto Jehovah’s Witnesses: A two-institutional experience.Onkologie 2004; 27: 131-137. DOI:10.1159/000076901.

  10. Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, FolkersA, Zeidan AM. Conviction in the face of affliction: a caseseries of Jehovah´s Witnesses with myeloid malignancies.Ann Hematol 2018; 97 (11): 2245-2248. https://doi.org/10.1007/s00277-018-3459-6.

  11. Emadi A, Bade NA, Stevenson B, Singh Z. Minimally-myelosuppressiveasparaginase-containing Induction regimenfor treatment of a Jehovah´s Witness with mutant IDH1/NOM1/NRAS acute myeloid leukemia. Pharmaceuticals(Basel) 2016; 9 (1): E12.

  12. Yammamoto Y, Kawashima A, Kashiwagi E, Ogata K. AJehovah’s witness with acute myeloid leukemia successfullytreated with and epigenetic drug, azacitidine:A clue for development of anti-AML therapy requiringminimum blood transfusions. Case Rep Hematol 2014;2014: 141260.

  13. Wilop S, Osieka R. Antineoplastic chemotherapy inJehovah´s Witness patients with acute myeloogenousleukemia refusing blood products- a matched pair analysis.Hematology 2018; 23 (6): 324-329.

  14. Dalal S, Boddapati M, Lowery MN, Veillon DM, Glass J,Munker R. Treatment of acute myeloid leukemia in aJehovah’s Witness. Ann Hematol 2006; 85 (6): 407-408.

  15. Cullis JO, Duncombe AS, Dudley JM, Lumley HS, ApperleyJF, Smith AG. Acute leukaemia in Jehovah’s Witnesses. BrJ Haematol 1998; 100 (4): 664-668.

  16. Tomado de https://www.jw.org /es/testigos-dejehov%C3%A1/por-todo-el-mundo/MX/.

  17. Ramírez-Salazar C, Jiménez-Corona ME, Rivera-CisnerosAE. Aspectos jurídicos en casos de transfusión sanguíneaen Testigos de Jehová. Gac Med Méx 2003; 139 (4):423-425.

  18. Tomado de https://www.elsoldemexico.com.mx/republica/sociedad/corte-y-testigos-de-jehova-se-enfrentan-porsalud-de-nina-con-cancer-en-chihuahua-1918806.html.

  19. Ferrer V, Glender W, Collazo J. Tratamiento de la leucemiaaguda linfoblástica con poliquimioterapia sin hemoderivadosen niños Testigos de Jehová. Rev Med Hosp Gen Mex

  20. 2009; 72 (1): 16-19.20. Swerdlow SH, Campo E, Pileri SA, Lee-Harris N, Stein H,Siebert R, Advani R, et al. The 2016 revision of the WorldHealth Organization classification of lymphoid neoplasms.Blood 2016: 127 (20): 2375-2390.

  21. Ramos C, Rozen E, León M, Martínez A, Olarte I, CastellanosH, Montaño E, et al. Results of treatment of acute lymphoblasticleukemia in two cohorts of Mexican patients. RevMed Chil 2011; 139 (9): 1135-1142.

  22. Koch TA, Myers J, Goodnough LT. Intravenous iron therapyin patients with iron deficiency anemia: Dosing considerations.Anemia 2015; 2015: 763576.

  23. Steele M, Narendran A. Mechanism of defective erythropoiesisand anemia in pediatric acute lymphoblasticleukemia (ALL). Ann Hematol 2012; 91 (10): 1513-1518.

  24. Teuffel O, Stanulla M, Cario G, Ludwig WD, Rottgers S, SchaferBW, Zimmermann M, Schrappe M, Niggli FK. Anemiaand survival in childhood acute lymphoblastic Leukemia.Haematologica 2008; 93 (11): 1652-1657.

  25. Cannas G, Thomas X. Supportive care in patients withacute leukaemia: historical perspectives. Blood Transfus2015; 13 (2): 205-220.

  26. Terwilliger T, M Abdul-Hay. Acute lymphoblastic leukemia:a comprehensive review and 2017 update. Blood CancerJ 2017; 7 (6): e577.

  27. Agapidou A, Vakalopoulou S, Papadopoulou T, ChadjiaggelidouC, Garypidou V. Successful treatment of severeanemia using erythropoietin in a Jehovah Witness withnon-Hodgkin lymphoma. Hematol Rep 2014; 6 (4): 5600.

  28. Ball AM, Winstead PS. Recombinant human erythropoietintherapy in critically ill Jehova’s Witnesses. Pharmatotherapy2008; 28 (11): 1383-1390.

  29. Beliaev AM. High-risk anaemic Jehovah’s Witness patientsshould be managed in the intensive care unit. Blood Transfus2013; 11 (3): 330-332.

  30. Lorentzen K, Kjaer B, Jørgensen J. Supportive treatment ofsevere anaemia in a Jehovah’s Witness with severe trauma.Blood Transfus 2013; 11 (3): 452-3.

  31. Yamamoto Y, Kawashima A, Kashiwagi E, Ogata K. AJehovah’s witness with acute myeloid leukemia successfullytreated with an epigenetic drug, azacitidine: A clue fordevelopment of anti-AML therapy requiring minimumblood transfusions. Case Rep Hematol 2014; 2014: 141260.

  32. Miao J, Leblebjian H, Scullion B, Parnes A. A single centerexperience with romiplostim for the management ofchemotherapy-induced thrombocytopenia. Am J Hematol2018; 93 (4): E86-E88.

  33. Bhatia M, Dacenport V, Cairo MS. The role of interleukin-11to prevent chemotherapy-induced thrombocytopeniain patients with solid tumors, lymphoma, acute myeloidleukemia and bone marrow failure syndromes. Leuk Lymphoma2007; 48 (1): 9-15.




2020     |     www.medigraphic.com